Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Receipt is acknowledged of Applicant’s Amendment filed on 08/20/2026.
Claims 1, 4, 6-7, 12 have been amended.
Claim 8 has been canceled.
Claims 1, 3-7, 9, 11-13, 15-16, 19-20, 24-25, 27-29 are pending in the instant application.
Claims 13, 15-16, 19-20, 24-25, 27-29 are withdrawn from consideration.
Note, rejections and objections not reiterated from previous office actions are hereby withdrawn. The following rejections or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1, 3-5, 7 is/are rejected under 35 U.S.C. 103 as being unpatentable over LIU et al (US 2017/0348442) in view of SHUEN (US 2017/0326252) and ZHONG et al (Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). International Journal of Oncology. 42: 373-383, 2013).
Regarding claims 1, 5, and 7, LIU teaches a composition comprised of: CCR2 binding peptide (see claim 1) for targeting CCR2 receptors, wherein the CCR2 binding peptide has TFLK sequence (see [0012]) and has no more than 200 amino acids, such as 7 amino acids (see SEQ ID NO: 2 at pg. 44; and [0093]); conjugated to a nanoparticle (see claim 1 and claim 8); a linker (see claim 1), such as TA-PEG-maleimide (see claim 10 at (vi)), which reads on PEG derivative, wherein the linker can be covalently attached to the nanoparticle (see [0017]; [0113]). Additional disclosures include: imaging agents (see abstract), such as a radiolabel (see claim 1), wherein the composition can be used to treat cancer (see [0027]), such as pancreatic cancer (see [0396]), and using a delivery system similar to that used for delivering chemotherapy to specific tumors (see [0187]).
LIU does not teach adding a chemotherapeutic agent conjugated to the nanoparticle with a second linker, such as cathepsin B-sensitive dipeptide linker.
SHUEN teaches the prior art had known of chemotherapeutic agents, such as MMAE (see [0055]) conjugated to a nanoparticle (see [0055]) with a linker, such as valine-citrulline and Phe-Lys (see [0055]-[0056]), which are cathepsin B-sensitive dipeptide linker (see [0055]). Additional disclosures include: chemotherapeutic agents, such as doxorubicin (see [0014]).
ZHONG teaches the prior art had known of using cathepsin B-cleavable doxorubicin for targeted cancer therapy (see abstract) achieves a higher DOX concentration in tumor tissue and a lower concentration in normal tissue, so as to enhance the efficacy and reduce toxicity to normal cells (see abstract).
It would have been obvious to the person of ordinary skill in the art at the time the invention was made to incorporate chemotherapeutic agent conjugated to the nanoparticle with a second linker, such as cathepsin B-sensitive dipeptide linker. The person of ordinary skill in the art would have been motivated to make those modifications, because it would have an additive effect in treating the cancer and lower toxicity, and reasonably would have expected success because the references dealt in the same field of endeavor, such as cancer treatment.
Regarding claim 3, LIN teaches the composition has a size of 5.0 nm (see [0247]).
Regarding claim 4, LIN teaches the nanoparticle can be nanocluster (see [0016]) and copper (see [0016]), thus, it would have been obvious to use nanoclusters of copper.
Claim(s) 1, 3-7, 9, 11-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over LIU et al (US 2017/0348442) in view of SHUEN (US 2017/0326252), ZHONG et al (Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). International Journal of Oncology. 42: 373-383, 2013) and NOVOBRANTSEVA et al (US 2021/0317461).
As discussed above, the references teach Applicant’s invention.
Regarding claim 6, the references teach the CCR2 binding peptide is ECL1i (see LIN at [0012), but does NOT teach that the chemotherapeutic agent is gemcitabine.
NOVOBRANTSEVA teaches the prior art had known of chemotherapeutic agents, such as doxorubicin and gemcitabine. Additional disclosures include: targeting CCR2 (see title), such as CCR2 peptide that consists of TFLK sequence (see [0208]).
It would have been obvious to the person of ordinary skill in the art at the time the invention was made to incorporate gemcitabine as the chemotherapeutic agents. The person of ordinary skill in the art would have been motivated to make those modifications and reasonably would have expected success because doxorubicin and gemcitabine are functional equivalents of chemotherapeutic agents.
Regarding claims 9, and 11-12, the references do NOT teach using immunotherapeutic agent, such as immune checkpoint inhibitor, such as anti-PD-1.
NOVOBRANTSEVA teaches the prior art had known of combination therapy for additive or synergistic effect (see [0037]), wherein combination with an addition agent such as an immune checkpoint therapy (see [0037]), such as PD-1 (see [0473] and [0476]). Immune checkpoints and their sequences are well-known in the art. Immune checkpoints generally relate to pairs of inhibitory receptors and the natural binding partners (see [0476]). Addition disclosures include: treatment of the associated cancer with a cancer therapy (e.g., anti-immune checkpoint, chemotherapeutic, and/or radiation therapy) (see [0064]).
It would have been obvious to the person of ordinary skill in the art at the time the invention was made to incorporate immunotherapeutic agent, such as immune checkpoint inhibitor, such as anti-PD-1. The person of ordinary skill in the art would have been motivated to make those modifications it would provide additive or synergistic effect and reasonably would have expected success because the prior art had now of using combination therapies for cancer treatment.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Telephonic Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAKE MINH VU whose telephone number is (571)272-8148. The examiner can normally be reached Mon-Fri 9:00am-5:30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JAKE M VU/Primary Examiner, Art Unit 1618